Efficacy of anti-GD2 antibody immunotherapy with filgrastim and teceleukin versus standard treatment with sargramostim, aldesleukin and isotretinoin in children with high-risk neuroblastoma

International Journal of Clinical Oncology · Published 2026-07-23 · DOI 10.1007/s10147-026-03142-8

Authors (11)

Chika Nitani, Junichi Hara, Hiroshi Kawamoto, Tomoaki Taguchi, Yuki Yuza, Shuhei Karakawa, Kimikazu Matsumoto, Toshimi Kimura, Kenichi Yoshimura, Kiyoshi Yoshimura, Akinobu Hamada

Abstract

PubPorta does not have an abstract for this article yet.

Read the article at the publisher →

Publication details

Year
2026

Citation

Nitani, C., Hara, J., Kawamoto, H., et al. (2026). Efficacy of anti-GD2 antibody immunotherapy with filgrastim and teceleukin versus standard treatment with sargramostim, aldesleukin and isotretinoin in children with high-risk neuroblastoma. International Journal of Clinical Oncology. https://doi.org/10.1007/s10147-026-03142-8

Related articles